Suppr超能文献

亲和体分子作为工程化蛋白质药物。

Affibody molecules as engineered protein drugs.

作者信息

Frejd Fredrik Y, Kim Kyu-Tae

机构信息

Affibody AB, Solna, Sweden.

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

出版信息

Exp Mol Med. 2017 Mar 24;49(3):e306. doi: 10.1038/emm.2017.35.

Abstract

Affibody molecules can be used as tools for molecular recognition in diagnostic and therapeutic applications. There are several preclinical studies reported on diagnostic and therapeutic use of this molecular class of alternative scaffolds, and early clinical evidence is now beginning to accumulate that suggests the Affibody molecules to be efficacious and safe in man. The small size and ease of engineering make Affibody molecules suitable for use in multispecific constructs where AffiMabs is one such that offers the option to potentiate antibodies for use in complex disease.

摘要

亲和体分子可作为诊断和治疗应用中分子识别的工具。关于这类替代支架分子在诊断和治疗方面的应用,已有多项临床前研究报道,目前早期临床证据也开始积累,表明亲和体分子在人体中有效且安全。亲和体分子体积小且易于工程化改造,适用于多特异性构建体,其中AffiMabs就是这样一种构建体,它为增强抗体在复杂疾病中的应用提供了选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ea8/5382565/84877a899912/emm201735f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验